Announced details
Development of therapeutic drugs for malignant melanoma, cosmetics and quasi-drug research, and improvement of skin blemishes
Multiple plant extracts showed significant effects in inhibiting cell proliferation and inducing cell death (specific figures: not disclosed).
The Company presented its research at the academic conference.
An academic conference on molecularly targeted cancer therapies, including treatments for malignant melanoma. Other details: not disclosed.
At this time, there is no impact on results for the current fiscal year
The company does not address Contract Value / Offering price.
30th Annual Meeting of the Japanese Association for Molecular Targeting of Cancer Therapy
| Item | Details |
|---|---|
| Names of Products / Services Covered | Research findings on malignant melanoma and skin pigmentation using plant extracts |
| Counterparty | 30th Annual Meeting of the Japanese Association for Molecular Targeting of Cancer Therapy |
| Counterparty overview | An academic conference on molecularly targeted cancer therapies, including treatments for malignant melanoma. Other details: not disclosed. |
| Relationship with the Company | The Company presented its research at the academic conference. |
| Launch date | 30 June to 2 July 2026 (conference dates and presentation period) |
| Applicable area | Development of therapeutic drugs for malignant melanoma, cosmetics and quasi-drug research, and improvement of skin blemishes |
| Quantitative Effects | Multiple plant extracts showed significant effects in inhibiting cell proliferation and inducing cell death (specific figures: not disclosed). |
| Impact on Business Performance | At this time, there is no impact on results for the current fiscal year |
| Source | 30th Annual Meeting of the Japanese Association for Molecular Targeting of Cancer Therapy |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Existing treatments for malignant melanoma face challenges including drug resistance and side effects, creating a need for therapeutic drugs with new mechanisms of action. In addition, excessive melanocyte activation is associated with pigmentation, and the research was considered potentially applicable to cosmetics and quasi-drug research.